1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/28225
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWoolley I.en
dc.contributor.authorHorne K.en
dc.date.accessioned2021-05-14T09:30:21Zen
dc.date.available2021-05-14T09:30:21Zen
dc.date.copyright2012en
dc.date.created20130129en
dc.date.issued2013-01-29en
dc.identifier.citationInfectious Disorders - Drug Targets. 12 (5) (pp 357-359), 2012. Date of Publication: 2012.en
dc.identifier.issn1871-5265en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/28225en
dc.description.abstractScientific drug design enables the production of novel agents that may be specific for individual malaria species, particularly by targeting their methods of cellular entry. Though there are practical and theoretical barriers to introducing novel agents into clinical practice, there may also be theoretical benefits to encourage further investigation of such agents, including a reduction in the rate of development of falciparum resistance. This paper discusses the potential risks and benefits such agents using the example of CCR5 blockers, drugs which are already in use for HIV treatment, but may be able to block DARC, the site of Plasmodium vivax into the human red blood cell. © 2012 Bentham Science Publishers.en
dc.languageenen
dc.languageEnglishen
dc.publisherBentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG, Netherlands)en
dc.titleShooting at the DARC: Potential issues with species-specific antimalarials.en
dc.typeArticleen
dc.identifier.affiliationInfectious Diseases and Clinical Microbiology-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.2174/187152612804142189en
dc.publisher.placeNetherlandsen
dc.identifier.pubmedid23017161 [http://www.ncbi.nlm.nih.gov/pubmed/?term=23017161]en
dc.identifier.source368100401en
dc.identifier.institution(Woolley, Horne) Departments of Infectious Diseases, Monash Medical Centre and Department of Medicine, Monash University, Clayton, VIC, Australiaen
dc.description.addressI. Woolley, Departments of Infectious Diseases, Monash Medical Centre and Department of Medicine, Monash University, Clayton, VIC, Australia. E-mail: ian.woolley@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2013 Elsevier B.V., All rights reserved.en
dc.subect.keywordsChemokine receptors DARC Malariaen
dc.identifier.authoremailWoolley I.; ian.woolley@monash.eduen
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeArticle-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptInfectious Diseases and Clinical Microbiology-
Appears in Collections:Articles
Show simple item record

Page view(s)

50
checked on Feb 11, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.